- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02563847
Effect of Amino Acids and Sugar Alcohols on Gastric Emptying and Release of Satiation Peptides in Humans
September 28, 2015 updated by: University Hospital, Basel, Switzerland
Effect of Amino Acids and Sugar Alcohols on Gastric Emptying and Release of Satiation Peptides in Normal Weight and Obese Subjects
With this study the investigators investigate the effects of amino acids (tryptophan in two different concentrations, leucin) and sugar alcohols (xylitol, erythritol) on satiety mechanisms.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Basel, Switzerland
- University Hospital Basel, Phase 1 Research Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy normal weight subjects with a body-mass index of 19.0-24.9
- Healthy obese subjects with a body-mass index of > 30
- Normal eating habits (no diets; no dietary changes; no special dietary habits, such as vegetarian/vegan)
- Age 18-40 years
- Stable body weight for at least three months
Exclusion Criteria:
- Smoking
- Substance abuse
- Regular intake of medications (except for oral contraceptives)
- Medical or psychiatric illness
- History of gastrointestinal disorders
- Food allergies
- Pregnancy, breast feeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 0.52 g L-Tryptophan
0.52 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
|
|
Active Comparator: 1.56 g L-Tryptophan
1.56 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
|
|
Active Comparator: 1.56 g L-Leucine
1.56 g L-Leucine in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
|
|
Active Comparator: 50 g Xylitol
50 g Xylitol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
|
|
Active Comparator: 75 g Erythritol
75 g Erythritol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
|
|
Placebo Comparator: 75 g Glucose
75 g Glucose in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
|
|
Placebo Comparator: Tap water
300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of different aminoacids and sugar alcohols on secretion of satiation hormones
Time Frame: changes from baseline to three hours after treatment
|
Plasma concentrations of glucose
|
changes from baseline to three hours after treatment
|
Effect of different aminoacids and sugar alcohols on secretion of satiation hormones
Time Frame: changes from baseline to three hours after treatment
|
Plasma concentrations of insulin are measured
|
changes from baseline to three hours after treatment
|
Effect of different aminoacids and sugar alcohols on secretion of satiation hormones
Time Frame: changes from baseline to three hours after treatment
|
Plasma concentrations of glucagon are measured
|
changes from baseline to three hours after treatment
|
Effect of different aminoacids and sugar alcohols on secretion of satiation hormones
Time Frame: changes from baseline to three hours after treatment
|
Plasma concentrations of glucagon-like Peptide (GLP-1) are measured
|
changes from baseline to three hours after treatment
|
Effect of different aminoacids and sugar alcohols on secretion of satiation hormones
Time Frame: changes from baseline to three hours after treatment
|
Plasma concentrations of PYY are measured
|
changes from baseline to three hours after treatment
|
Effect of different aminoacids and sugar alcohols on secretion of satiation hormones
Time Frame: changes from baseline to three hours after treatment
|
Plasma concentrations of cholecystokinin are measured
|
changes from baseline to three hours after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of different aminoacids and sugar alcohols on gastric emptying
Time Frame: changes from baseline to four hours after treatment
|
measured by C13 breath test
|
changes from baseline to four hours after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2014
Primary Completion (Actual)
March 1, 2015
Study Registration Dates
First Submitted
May 26, 2015
First Submitted That Met QC Criteria
September 28, 2015
First Posted (Estimate)
September 30, 2015
Study Record Updates
Last Update Posted (Estimate)
September 30, 2015
Last Update Submitted That Met QC Criteria
September 28, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EKBB 2014/072
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endocrine System Diseases
-
National Institute of Diabetes and Digestive and...RecruitingEndocrine DiseasesUnited States
-
University of TennesseeCompletedEndocrine Disorders of Female Reproductive SystemUnited States
-
University of TennesseeCompletedEndocrine Disorders of Female Reproductive SystemUnited States
-
Tongji HospitalGeneScience Pharmaceuticals Co., Ltd.Recruiting
-
Eunice Kennedy Shriver National Institute of Child...Terminated
-
M.D. Anderson Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
Stanford UniversityCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteGenentech, Inc.TerminatedPancreatic CancerUnited States
-
Central Hospital, Nancy, FranceRecruiting
-
National Institute of Diabetes and Digestive and...Recruiting
Clinical Trials on 1.56 g L-Tryptophan
-
University Hospital, Basel, SwitzerlandCompletedEndocrine System DiseasesSwitzerland
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); National Research Agency, FranceCompletedDiet ModificationCanada
-
John D. Dingell VA Medical CenterWithdrawnDepressionUnited States
-
University of Colorado, DenverCompletedPost-operative DeliriumUnited States
-
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical...CompletedHealthy | Chronic Kidney DiseasesTaiwan
-
University of OregonNational Institute on Aging (NIA); Oregon Health and Science University; University... and other collaboratorsUnknownQuality of Life | Muscle AtrophyUnited States
-
KU LeuvenRecruitingStress, PsychologicalBelgium
-
Hospital Civil de GuadalajaraNot yet recruitingArginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth CurveFetal Growth Retardation
-
Valenta Pharm JSCCompletedAnxiety | Adjustment Disorders | NeurastheniaRussian Federation
-
Barbara Ann Karmanos Cancer InstituteWashington University School of MedicineRecruitingBreast Cancer | Rectal Cancer | Neuroendocrine Tumors | Metastatic Brain Tumor | Intracranial GliomaUnited States